Senphonix
Senphonix
  • Home
  • Solution
  • Team
  • Partners
  • Press
  • Contact
  • More
    • Home
    • Solution
    • Team
    • Partners
    • Press
    • Contact
  • Home
  • Solution
  • Team
  • Partners
  • Press
  • Contact

An architecture that can be easily adopted

Monitoring that works within the workflow, not on top of it.

SleeveSense™ captures vital signs continuously and automatically, with nothing for nurses to start, manage, or charge, and nothing for patients to operate. It delivers data where clinicians already work and leaves clinical judgment where it belongs.


A long-term wearable, built to disappear.

SleeveSense is a soft, patent-pending sleeve worn on the upper arm, with no adhesives and no straps. It is designed to be worn comfortably for days, weeks, or months, through showering, sleeping, and everyday activity, and it charges wirelessly while worn. It captures heart rate, respiration rate, skin temperature, and movement continuously, and is built to clinical-grade accuracy, which we are validating in clinical testing.


The automation is the product.
Most monitoring adds work. SleeveSense removes it.

  • For nurses: no measurements to start, no devices to manage, no batteries to swap, no charging to supervise.
  • For patients: nothing to operate, wear differently, or remember. No change in behavior.
  • Always on: monitoring runs continuously, regardless of location or time of day.



   “If I have to manage another device, charge something, or remind patients to use it, it is not going to last. Automation only works if it disappears into the background.” 

Connected everywhere the patient goes.

In the hospital, SleeveSense connects over long-range (LoRa) radio paired with a dedicated cellular link to the Senphonix cloud. It runs independently of hospital networks, so there is no strain on existing infrastructure and no upgrades required. At home, SleeveSense switches automatically to Bluetooth through the patient’s smartphone. The experience stays completely passive, and monitoring continues without interruption.


Data where clinicians already work.

Vitals are exposed through a secure API on a HIPAA-compliant cloud running on Microsoft Azure. The electronic health record pulls readings when clinicians choose to review them, and existing hospital alerting systems reach the data through the EHR. Senphonix does not set thresholds, generate its own alerts, or push data automatically. That keeps clinical governance with the care team and avoids adding to alarm fatigue.


Secure at every step, by default.

  • Bluetooth: Secure Connections (Bluetooth 4.2+) with AES-128 encryption and ECDH key exchange; data travels to Azure over TLS 1.2 or 1.3.
  • LoRa: LoRaWAN 1.1+ with AES-128 encryption on the device-to-gateway link, then TLS 1.2 or 1.3 from gateway to network server and on to the cloud.
  • In the cloud: AES-256 encryption at rest, TLS in transit, and access and key management through Azure Key Vault.


Security architecture is designed to HIPAA and HITECH requirements, with SOC 2 Type II readiness underway.


No capital purchase. No idle cost.

Senphonix provides and manages all of the infrastructure, the sleeves, the radios, and the chargers, with no capital outlay for the health system. Pricing is a per-patient subscription for inpatients and a per-patient, per-month subscription for outpatients, so cost scales with use and you never pay for unused capacity.


What it adds up to.

  • Time returned to nurses, by removing manual vital-sign work.
  • Earlier awareness of a patient’s changing condition, across the full care continuum.
  • A path to fewer readmissions and new remote-patient-monitoring revenue.

a Smooth patient journey

 “Thank you for thinking about nurses.” 

“The appeal here is that the data arrives without us having to redesign workflows or add headcount.” 

If you'd like a copy of our white paper on this topic, reach out.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SleeveSense™ will be available upon FDA clearance, which is expected in 2027.


Senphonix is a Delaware C-Corp., with offices in Minnesota and Arizona. For more information, contact us at info@senphonix.com or 612-913-0607; or follow us on LinkedIn. Copyright © 2026 Senphonix, Inc. - All Rights Reserved. Logos and trademarks are the property of their respective owners. All quotes herein are drawn from anonymous responses to two MarketWise Advising ("MarketWise") national studies, commissioned by Senphonix; some quotes were lightly edited for brevity. 

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept